Alpha 2.0
Login Register
» Authors » Konstantinos Stefanakis

Konstantinos Stefanakis

Explore the profile of Konstantinos Stefanakis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 128
Followers 0
Related Specialties
Endocrinology
Biology
Gastroenterology
Top 10 Co-Authors
Christos S Mantzoros
Alexander Kokkinos
Laura Valenzuela-Vallejo
Stamatia Simati
Nikolaos Perakakis
Chrysoula Boutari
Margery A Connelly
Ajay Kumar
Georgia Argyrakopoulou
Angeliki M Angelidi
Published In
Metabolism
Diabetes Obes Metab
Nat Commun
Endocr Rev
Hepatol Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Apolipoprotein CIII correlates with lipoproteins in the fed state and is not regulated by leptin administration in states of hypoleptinemia induced by acute or chronic energy deficiency: Results from two randomised controlled trials
Ramirez-Cisneros A, Stefanakis K, Mantzoros C
Diabetes Obes Metab . 2025 Jan; 27(4):2012-2023. PMID: 39810632
Background: Medications targeting the leptin and Apolipoprotein CIII (APOC3) pathways are currently under development for the treatment of hypertriglyceridaemia. Given that both pathways are implicated in triglyceride regulation, it is...
2.
Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables
Stefanakis K, Mingrone G, George J, Mantzoros C
Metabolism . 2024 Nov; 163:156082. PMID: 39566717
Background: There are no known non-invasive tests (NITs) designed for accurately detecting metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2-F3, excluding cirrhosis-the FDA-defined range for prescribing Resmetirom and other...
3.
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Stefanakis K, Kokkorakis M, Mantzoros C
Metabolism . 2024 Oct; 161:156057. PMID: 39481534
Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight loss in many patients, i.e., at a rate approaching that achieved...
4.
Leptin physiology and pathophysiology in energy homeostasis, immune function, neuroendocrine regulation and bone health
Stefanakis K, Upadhyay J, Ramirez-Cisneros A, Patel N, Sahai A, Mantzoros C
Metabolism . 2024 Oct; 161:156056. PMID: 39481533
Since its discovery and over the past thirty years, extensive research has significantly expanded our understanding of leptin and its diverse roles in human physiology, pathophysiology and therapeutics. A prototypical...
5.
Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
Anastasiou G, Stefanakis K, Hill M, Mantzoros C
Metabolism . 2024 Oct; 161:156044. PMID: 39362519
No abstract available.
6.
Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects
Stefanakis K, Samiotaki M, Papaevangelou V, Valenzuela-Vallejo L, Giannoukakis N, Mantzoros C
Metabolism . 2024 Aug; 159:155984. PMID: 39097160
Background: Leptin is known for its metabolic, immunomodulatory and neuroendocrine properties, but the full spectrum of molecules downstream of leptin and relevant underlying mechanisms remain to be fully clarified. Our...
7.
Total and H-specific GDF-15 levels increase in caloric deprivation independently of leptin in humans
Chrysafi P, Valenzuela-Vallejo L, Stefanakis K, Kelesidis T, Connelly M, Mantzoros C
Nat Commun . 2024 Jun; 15(1):5190. PMID: 38890300
Mitochondrial-secreted growth differentiation factor-15 (GDF-15) promotes weight loss in animals. Its effects in humans remain unclear, due to limited research and potential measurement interference from the H202D-variant. Our post-hoc analysis...
8.
Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity
Boutari C, Stefanakis K, Simati S, Guatibonza-Garcia V, Valenzuela-Vallejo L, Anastasiou I, et al.
Cardiovasc Diabetol . 2024 May; 23(1):174. PMID: 38762719
Background: Growth differentiation factor 15 (GDF15) is a mitokine, the role of which, total or H-specific, in modulating energy metabolism and homeostasis in obesity-related diseases, such as metabolic dysfunction associated...
9.
Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration
Konstantinidou S, Argyrakopoulou G, Simati S, Stefanakis K, Kokkinos A, Analitis A, et al.
Diabetes Obes Metab . 2024 May; 26(8):3147-3154. PMID: 38757729
Aim: To investigate growth/differentiation factor 15 (GDF-15) levels in response to antiobesity medications, namely, liraglutide (Lira) and naltrexone/bupropion (N/B), in individuals with overweight or obesity. Materials And Methods: This was...
10.
Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments
Angelidi A, Stefanakis K, Chou S, Valenzuela-Vallejo L, Dipla K, Boutari C, et al.
Endocr Rev . 2024 Mar; 45(5):676-708. PMID: 38488566
Research on lean, energy-deficient athletic and military cohorts has broadened the concept of the Female Athlete Triad into the Relative Energy Deficiency in Sport (REDs) syndrome. REDs represents a spectrum...